Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.67 |
| ▸ | GAA | P10253 | 2/20 | 0.62 |
| ▸ | APAF1 | O14727 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 3/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethane SCHEMBL11828584 | 0.98 | ALDH1A1 (0.65) | ALDH1A1GAAAPAF1HTTTP53 | |
| SCHEMBL15231004 | 0.85 | APAF1 (0.56) | ALDH1A1GAAAPAF1HTTTP53 | |
| SCHEMBL11635641 | 0.85 | ALDH1A1 (0.56) | ALDH1A1GAAAPAF1HTTTP53 | |
| SCHEMBL15229912 | 0.80 | APAF1 (0.55) | ALDH1A1GAAAPAF1HTTLMNA | |
| SCHEMBL15230043 | 0.80 | APAF1 (0.51) | ALDH1A1GAAAPAF1HTTTP53 | |
| SCHEMBL13066493 | 0.80 | ALDH1A1 (1.00) | ALDH1A1GAAAPAF1LMNA | |
| SCHEMBL21628148 | 0.79 | KDM4E (0.51) | ALDH1A1GAAAPAF1HTTLMNA | |
| SCHEMBL15230436 | 0.79 | APAF1 (0.50) | ALDH1A1APAF1HTTLMNACYP2C19 | |
| SCHEMBL18554457 | 0.79 | GAA (0.51) | ALDH1A1GAAAPAF1HTTTP53 | |
| SCHEMBL1852463 | 0.79 | KMT2A (0.56) | ALDH1A1GAAAPAF1HTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3042907-B1 | DGAT1 INHIBITOR AND PREPARATION METHOD AND USE THEREOF | QUINGDAO HUANGHAI PHARMACEUTICAL CO LTD (CN) | 2021-01-13 | — | — | EP | disclosed |
| US-9809604-B2 | DGAT1 inhibitor and preparation method and use thereof | QINGDAO HUANGHAI PHARMACEUTICAL CO., LTD. (CN) | 2017-11-07 | — | — | US | disclosed |
| US-20160272651-A1 | DGAT1 Inhibitor and Preparation Method and Use Thereof | QINGDAO HUANGHAI PHARMACEUTICAL CO., LTD. (CN) | 2016-09-22 | — | — | US | disclosed |
| US-9434743-B2 | Indazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-09-06 | — | — | US | disclosed |
| EP-3042907-A1 | DGAT1 INHIBITOR AND PREPARATION METHOD AND USE THEREOF | Medshine Discovery Inc. (CN) | 2016-07-13 | — | — | EP | disclosed |
| US-20150005232-A1 | INDAZOLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (US) | 2015-01-01 | — | — | US | disclosed |
| EP-1324990-B1 | MORPHOLIN-ACETAMIDE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LTD (GB) | 2014-10-29 | — | — | EP | disclosed |
| WO-2013130855-A1 | INDAZOLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-09-06 | — | — | WO | disclosed |
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2010-11-11 | — | — | US | disclosed |
| US-7560548-B2 | Morpholin-acetamide derivatives for the treatment of inflammatory diseases | GLAXO GROUP LIMITED (GB) | 2009-07-14 | — | — | US | disclosed |
| US-20090163495-A1 | MORPHOLIN-ACETAMIDE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2009-06-25 | — | — | US | disclosed |
| EP-1962605-A2 | 2-ARYLTHIAZOLE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007070433-A2 | 2-ARYLTHIAZOLE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| US-7101882-B2 | Morpholin-acetamide derivatives for the treatment of inflammatory diseases | GLAXO GROUP LIMITED (GB) | 2006-09-05 | — | — | US | disclosed |
| US-20060079525-A1 | Morpholin-acetamide derivatives for the treatment of inflammatory diseases | ANCLIFF RACHAEL A | 2006-04-13 | — | — | US | disclosed |
| US-20050222147-A1 | Process for the preparation of morpholine derivatives and intermediates therefore | GLAXO GROUP LIMITED (GB) | 2005-10-06 | — | — | US | disclosed |
| US-20040058923-A1 | Morpholin-acetamide derivatives for the treatment of inflammatory diseases | SMITHKLINE BEECHAM CORPORATION | 2004-03-25 | — | — | US | disclosed |
| EP-1324990-A1 | MORPHOLIN-ACETAMIDE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2003-07-09 | — | — | EP | disclosed |
| WO-2002026722-A1 | MORPHOLIN-ACETAMIDE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2002-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005232-A1 | INDAZOLE DERIVATIVES | GPR119, INSR, INSRR | ALDH1A1 511/4885GAA 1384/4885APAF1 4736/4885 |
| US-20040058923-A1 | Morpholin-acetamide derivatives for the treatment of inflammatory diseases | CCR1, MALT1, REL | ALDH1A1 3130/4885GAA 2234/4885APAF1 4569/4885 |
| US-20160272651-A1 | DGAT1 Inhibitor and Preparation Method and Use Thereof | DGAT1, DGAT2, LCAT | ALDH1A1 1707/4885GAA 164/4885APAF1 3494/4885 |
| US-20050222147-A1 | Process for the preparation of morpholine derivatives and intermediates therefore | NISCH, MYO3B, CYP11B2 | ALDH1A1 1003/4885GAA 964/4885APAF1 4421/4885 |
| US-20060079525-A1 | Morpholin-acetamide derivatives for the treatment of inflammatory diseases | ARG1, ARG2, NFKBIA | ALDH1A1 1688/4885GAA 1530/4885APAF1 2966/4885 |
| US-20090163495-A1 | MORPHOLIN-ACETAMIDE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | ARG1, ARG2, NFKBIA | ALDH1A1 1688/4885GAA 1530/4885APAF1 2966/4885 |
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | CXCR3, CXCR1, CXCR2 | ALDH1A1 971/4885GAA 4433/4885APAF1 2577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.